

MOLNUPIRAVIR PRESCRIPTION (non-hospitalised)

Write in CAPITAL LETTERS or use addressograph

Health and Care No: _____

Surname: _____

First names: _____

DOB: _____

Phone: _____

Allergies / Medicine Sensitivities
No known allergies <input type="checkbox"/> (please tick) or
Medicines (generic) / allergen (type of reaction)
Weight _____

Treatment to commence on:	Delivery arrangements:
Address if for delivery:	<input type="radio"/> Send to : _____
	<input type="radio"/> To be collected in pharmacy by: _____

Inclusion Criteria (ALL MUST APPLY)	Indicate Yes or No
SARS-CoV-2 infection is confirmed by either PCR testing or lateral flow test (registered via gov.uk or NHS 119)	
Symptomatic with COVID-19 and showing no signs of clinical recovery	
Patient is a member of a 'highest' risk group (as detailed in the Department of Health and Social Care commissioned Independent Advisory Group Report)	Please state risk group:
Treatment with nirmatrelvir/ritonavir (Paxlovid®) (1 st line), sotrovimab (2 nd line) are contraindicated or not clinically suitable.	
Treatment with remdesivir (3 rd line) is contraindicated, not clinically suitable or not available.	
Treatment is commenced within FIVE days of symptom onset	
Exclusion Criteria (Patients are not eligible if they meet any of the following)	Indicate Yes or No
Requirement for hospitalisation for COVID-19	
Known hypersensitivity reaction to the active substances or to any of the excipients of the products as listed in the Summary of Product Characteristics (SmPC)	
New supplemental oxygen requirements specifically for the management of COVID-19 symptoms	
Age less than 18 years	
Pregnancy	

Prescribed and non-prescribed medications have been reviewed (please tick box and sign) Signature:.....

Additional Information:

- As molnupiravir is **not recommended during pregnancy**, all individuals of childbearing potential who are prescribed molnupiravir should be advised to use effective contraception during treatment and for 4 days post treatment. Breast-feeding is not recommended during treatment and for 4 days after the last dose. Further information can be sought from email ukdilas.enquiries@nhs.net.
- All healthcare professionals are asked to ensure that any patients who receive a COVID antiviral while pregnant are reported to the UK COVID-19 antivirals in pregnancy registry on 0344 892 0909 so that they can be followed up.
- If a dose is missed within 10 hours of the time it is usually taken, take as soon as possible and resume the normal dosing schedule. If a dose missed by more than 10 hours, **do not** take the missed dose and instead take the next dose at the regularly scheduled time.
- No dose reductions required in renal/hepatic impairment and no drug interactions have been identified based on the limited available data.
- See SPC for further information [Lagevrio 200 mg hard capsules - Summary of Product Characteristics \(SmPC\) - \(emc\) \(medicines.org.uk\)](#)
- There is no interaction expected between remdesivir or molnupiravir and other commissioned treatments for COVID-19. For further information please visit the [University of Liverpool COVID-19 Drug Interactions website](#)
- It is vital that any suspected adverse reactions are reported directly to the MHRA via the new dedicated COVID-19 [Yellow card reporting site](#)
- **NOTE**** If a patient requires hospitalisation due to severe or critical COVID-19 after starting treatment with molnupiravir, the patient should complete the full 5-day treatment course at the discretion of his/her healthcare provider.

Advice to be given to the patient by the prescriber:

- Can be taken with or without food
- The most common adverse reactions reported during treatment and for 14 days after the last dose are mild to moderate diarrhoea, nausea, dizziness and headache.

Drug	Dose & Frequency	Route	Duration
Molnupiravir	800mg (four 200mg capsules) twice daily	Oral	5 days
Prescriber's Signature	Print Name	Date	
Pharmacy Section:			
CC	LAB	DISP	FC
			Date: